Lux funds lift Eikon Therapeutics (EIKN) stake via IPO conversions, buys
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Eikon Therapeutics, Inc. reported insider transactions by Lux-affiliated investment entities related to its IPO. On February 4, 2026, Lux Co-Invest Opportunities II, L.P. and Lux Total Opportunities, L.P. each indirectly bought 138,888 shares of common stock at $18 per share in open-market purchases.
On February 6, 2026, several Lux funds indirectly acquired common stock through conversions of preferred stock, including 10,000,000 shares of Series A Preferred Stock and multiple series of A-1, B, B-1, C, C-1 and D Preferred Stock. These preferred shares converted into common stock immediately prior to the closing of Eikon’s initial public offering on a 1-for-7.4578 basis. The Lux entities report indirect beneficial ownership, and the managing members, including director Josh Wolfe and Peter Hebert, disclaim beneficial ownership except to the extent of their pecuniary interests.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 277,776 shares ($4,999,968)
Net Buy
15 txns
Insider
Lux Venture Partners V, LLC, Wolfe Josh, Hebert Peter, Lux Ventures V, L.P., Lux Co-Invest Opportunities II, L.P., Lux Total Opportunities, L.P.
Role
10% Owner | Director, 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner
Bought
277,776 shs ($5.00M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series A Preferred Stock | 10,000,000 | $0.00 | -- |
| Conversion | Series A-1 Preferred Stock | 7,807,026 | $0.00 | -- |
| Conversion | Series A-1 Preferred Stock | 2,502,252 | $0.00 | -- |
| Conversion | Series B Preferred Stock | 796,380 | $0.00 | -- |
| Conversion | Series B Preferred Stock | 530,920 | $0.00 | -- |
| Conversion | Series B-1 Preferred Stock | 5,289,322 | $0.00 | -- |
| Conversion | Series B-1 Preferred Stock | 3,526,215 | $0.00 | -- |
| Conversion | Series C Preferred Stock | 303,360 | $0.00 | -- |
| Conversion | Series C-1 Preferred Stock | 1,450,614 | $0.00 | -- |
| Conversion | Series D Preferred Stock | 10,266,152 | $0.00 | -- |
| Conversion | Common Stock | 2,387,705 | $0.00 | -- |
| Conversion | Common Stock | 1,151,540 | $0.00 | -- |
| Conversion | Common Stock | 2,155,765 | $0.00 | -- |
| Purchase | Common Stock | 138,888 | $18.00 | $2.50M |
| Purchase | Common Stock | 138,888 | $18.00 | $2.50M |
Holdings After Transaction:
Series A Preferred Stock — 0 shares (Indirect, See Footnote);
Series A-1 Preferred Stock — 0 shares (Indirect, See Footnote);
Series B Preferred Stock — 0 shares (Indirect, See Footnote);
Series B-1 Preferred Stock — 0 shares (Indirect, See Footnote);
Series C Preferred Stock — 0 shares (Indirect, See Footnote);
Series C-1 Preferred Stock — 0 shares (Indirect, See Footnote);
Series D Preferred Stock — 0 shares (Indirect, See Footnote);
Common Stock — 2,387,705 shares (Indirect, See Footnote)
Footnotes (1)
- These shares are held by Lux Co-Invest Opportunities II, L.P. ("LCIO II"). Lux Co-Invest Partners II, LLC ("LCIP II") is the general partner of LCIO II and exercises voting and dispositive power over the shares noted herein held by LCIO II. Peter Hebert and Josh Wolfe, a member of the Issuer's board of directors (the "Individual Lux Managers"), are the individual managing members of LCIP II. The Individual Lux Managers, and as the sole managers of LCIP II, may be deemed to beneficially own the shares held by LCIO II. Each of LCIP II and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein. These shares are held by Lux Total Opportunities, L.P. ("LTO"). Lux Total Opportunities Partners, LLC ("LTOP") is the general partner of LTO and exercises voting and dispositive power over the shares noted herein held by LTO. The Individual Lux Managers are the individual managing members of LTOP. The Individual Lux Managers, as the sole managers of LTOP, may be deemed to beneficially own the shares held by LTO. Each of LTOP and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein. The Series A Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") on a 1-for-7.4578 basis and had no expiration date. The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. These shares are held by Lux Ventures V, L.P. ("LVV"). Lux Venture Partners V, LLC ("LVPV") is the general partner of LVV and exercises voting and dispositive power over the shares noted herein held by LVV. The Individual Lux Managers are the individual managing members of LVPV. The Individual Lux Managers, as the sole managers of LVPV, may be deemed to beneficially own the shares held by LVV. Each of LVPV and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein. The Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. The Series B-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. The Series C-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.
FAQ
What insider transactions did Lux entities report in Eikon Therapeutics (EIKN)?
Lux-affiliated funds reported open-market purchases of Eikon common stock and conversions of multiple preferred stock series into common shares. The activity reflects indirect holdings by funds such as Lux Ventures V, L.P., Lux Co-Invest Opportunities II, L.P., and Lux Total Opportunities, L.P.
What preferred stock series in Eikon Therapeutics (EIKN) were converted by Lux funds?
Lux funds reported conversions of Series A, Series A-1, Series B, Series B-1, Series C, Series C-1, and Series D Preferred Stock. Footnotes state each series converted into common stock immediately prior to the IPO closing on a 1-for-7.4578 basis with no expiration date.